German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm;S1-leitlinie der DGRh zur sequenziellen medikamentösen therapie der rheumatoiden arthritis 2012: Adaptierte EULAR-empfehlungen und aktualisierter therapiealgorithmus

Zeitschrift fur Rheumatologie

Volumn 71, Issue 7, 2012, Pages 592-603

  Kruger K ^a   Wollenhaupt, J ^b   Albrecht, K ^c   Alten, R ^d   Backhaus, M ^e   Baerwald, C ^f   Bolten, W ^g   Braun, J ^h   Burkhardt, H ⁱ   Burmester, G ^j   Gaubitz, M ^k   Gause, A ^l   Gromnica Ihle, E ^m   Kellner, H ⁿ   Kuipers, J ^o   Krause, A ^p   Lorenz, H M ^q   Manger, B ^r   Nußlein H ^s   Pott, H G ^t   Rubbert Roth, A ^u   Schneider, M ^v   Specker, C ^w   Schulze Koops, H ^x   Tony, H P ^y   Wassenberg, S ^z   Muller Ladner U ^aa   more..

^a Praxiszentrum Rheumatologie   (Germany)

^b Hamburg Center for Pediatric and Adolescent Rheumatology   (Germany)

^c Deutsche Gesellschaft für Rheumatologie DGRh   (Germany)

^d Schlosspark Klinik   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g Klaus Miehlke Klinik   (Germany)

^h RHEUMAZENTRUM RUHRGEBIET   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k Schwerpunktpraxis für Rheumatologie und Autoimmunerkrankungen   (Germany)

^l Bundesverband Pharmazeutischen I   (Germany)

^m Krankenhaus Neuwittelsbach   (Germany)

ⁿ Rotes Kreuz Krankenhaus Bremen   (Germany)

^o MARTIN LUTHER KRANKENHAUS   (Germany)

^p UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^q Rheumazentrum   (Germany)

^r UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^s Internistisch rheumatologische Schwerpunktpraxis   (Germany)

^t Rheumatologikum Hannover   (Germany)

^u UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^v HEINRICH HEINE UNIVERSITY   (Germany)

^w Eye Hospital   (Germany)

^x LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^y UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^z Evangelisches Fach krankenhaus Ratingen   (Germany)

^aa JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

Biological agents; Disease modifying antirheumatic drugs; Glucocorticoids; Medical treatment; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE;

ALGORITHM; ARTICLE; HUMAN; PRACTICE GUIDELINE; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84866885065     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-012-1038-0     Document Type: Article

References (75)

1. Albrecht K, Krüger K, Müller-Ladner U, Wollenhaupt J (2012) Systematische Literaturrecherche für die S1-Leitlinie zur sequentiellen medikamentösen Therapie der rheumatoiden Arthritis. Z Rheum
2. Aletaha D, Neogi T, Silman A et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581
3. Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 29:1631-1638
4. Bakker MF, Jacobs JW, Welsing PM et al (2011) Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 70:1099-1103
5. Bathon J, Robles M, Ximenes AC (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70:1949-1956
6. Bosello S, Fedele AL, Peluso G et al (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 70:1292-1295
7. Britsemmer K, Ursum J, Gerritsen M et al (2011) Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann Rheum Dis 70:1468-1470
8. Brocq O, Millasseau E, Albert C et al (2009) Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 76:350-355
9. Cader MZ, Filer A, Hazlehurst J et al (2011) Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 70:949-955
10. Chatzidionysiou K, Lie E, Nasonov E et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374-377
11. Criswell LA, Such CL, Yelin EH (1997) Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol 24:2283-2290
12. Curtis JR, Yang S, Chen L et al (2012) Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis 71:206-212
13. De Boer KV, Visser K, Ronday HK et al (2010) Induction therapy with methotrexate and prednisone in rheumatoid or very early arthritic disease: IMPROVED study. Arthritis Rheum 62(Suppl 10):1396
14. Dougados M, Huizinga T, Sheeran T et al (2011) Tocilizumab plus methotrexate does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results of the ACT-RAY study. Ann Rheum Dis 70(Suppl 3):73
15. Emery P, Durez P, Dougados M et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510-516
16. Engström A, Saevarsdottir S, Rezaei H et al (2011) Development of a matrix risk model for prediction of rapid radiographic progression based on the Swefot trial population. Ann Rheum Dis 70(Suppl 3):77
17. Finckh A, Dehler S, Gabay C et al (2009) The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 68:33-39
18. Gaujoux-Viala C, Smolen JS, Landewe R et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1004-1009
19. Hafstrem I, Albertsson K, Boonen A et al (2009) Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 68:508-513
20. Haraoui B, Emery P, Mozaffarian N et al (2010) Change in CRP at 12 weeks predicts the risk of rapid radiographic progression at 2 years in methotrexate-treated patients with early rheumatoid arthritis. Arthritis Rheum 62(Suppl 10):1101
21. Hetland ML, Stengaard-Pedersen K, Junker P et al (2010) Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomized CIMESTRA trial. Ann Rheum Dis 69:1789-1795
22. Hoes JN, Jacobs JWG, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560-1567
23. Ichikawa Y, Saito T, Yamanaka H et al (2010) Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 37:723-729
24. Katchamart W, Trudeau J, Phumethum V, Bombardier C (2010) Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying antirheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 4:S CD008495
25. Keystone E, Ogale S, Devenport J, Lepley D (2011) Benefit of continuing tocilizumab therapy (8 mg/kg every 4 weeks) in rheumatoid arthritis patients who have not responded adequately within the first 8 weeks. Ann Rheum Dis 70(Suppl 3):461
26. Kievit W, Fransen J, Adang EM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 50:196-203
27. Kirwan JR, Bijlsma JW, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 24:CD006356
28. Klarenbeek NB, Kooij SM van der, Güler-Yüksel M et al (2011) Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 70:315-319
29. Klarenbeek NB, Güler-Yüksel M, Kooij SM van der et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039-1046
30. Kremer JM, Genovese MC, Cannon GW (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726-733
31. Lacaille D, Anis AH, Guh DP, Esdaile JM (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 53:241-248
32. Lard LR, Visser H, Speyer I et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446-451
33. Liao KP, Weinblatt ME, Cui J et al (2011) Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Rheumatology 50:1473-1479
34. Mease PJ (2010) Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol 37:1570-1578
35. Müller-Ladner U (2009) Unifying abbreviations for biologics in rheumatology-does the idea hold promise? Rheumatology 48:704
36. Nam JL, Winthrop KL, Vollenhoven RF van (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976-986
37. Navarro-Sarrabia F, Ruiz-Montesinos D, Hernandez B et al (2009) DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMJ Muskuloskeletal Disorders 10:91
38. Nell VP, Machold KP, Eberl G et al (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43:906-914
39. O'Dell JR, Leff R, Paulsen G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164-1170
40. O'Mahony R, Richards A, Deighton C, Scott D (2010) Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 69:1823-1826
41. Pincus T, Yazici Y, Sokka T et al (2003) Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21(Suppl 31):179-185
42. Rantalaiho V, Korpela M, Hannonen P et al (2009) The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 60:1222-1231
43. Rezaei H, Saevarsdottir S, Forslind K et al (2012) In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 71:186-191
44. Roddy E, Zhang W, Doherty M et al (2006) Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 12:347-352
45. Salliot C, Heijde D van der (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100-1104
46. Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo-or ciclosporin-controlled trials. Clin Drug Investig 30:613-624
47. Schipper LG, Fransen J, Broeder AA den, Van Riel PL (2010) Time to achieve remission determines time to be in remission. Arthritis Res Ther 12:R97
48. Schipper LG, Fransen J, Barrera P et al (2009) Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? Rheumatology 48:1247-1253
49. Schneider M, Lelgemann M, Abholz HH et al (2011) Management der frühen rheumatoiden Arthritis. Interdisziplinäre Leitlinie, 3. überarbeitete Aufl. Steinkopf, Darmstadt
50. Schoels M, Wong J, Scott DL et al (2010) Economic aspects of treatment options in rheumatoid arthritis: a systematic review informing the EULAR recommenations for the management of rheumatoid arthritis. Ann Rheum Dis 69:955-1003
51. Sibilia J, Graninger W, Östör A et al (2011) Comparison of tocilizumab as monotherapy or with add-on DMARDs in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 70(Suppl 3):466
52. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975
53. Smolen JS, Fleischmann R, Emery P et al (2011) The OPTIMA study of methotrexate and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. Ann Rheum Dis 70(Suppl 3):259
54. Soubrier M, Puéchal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48:1429-1434
55. Soubrier M, Lukas C, Sibilia J et al (2011) Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 70:611-615
56. Strangfeld A, Hierse F, Kekow J et al (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856-1862
57. Svensson B, Boonen A, Albertsson K et al (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52:3360-3370
58. Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286-1291
59. Tarner IH, Manger B, Fleck E et al (2009) Evidenzbasierte Empfehlungen einer nationalen Expertenrunde zum Einsatz von Methotrexat bei entzündlich-rheumatischen Erkrankungen. Akt Rheum 34:59-66
60. Tiippana-Kinnunen T, Paimela L, Kautiainen H et al (2010) Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheum 39:12-18
61. Todoerti M, Scire CA, Boffini N et al (2010) Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci 1193:139-145
62. Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med 333:137-141
63. Van den Broek M, Klarenbeek NB, Dirven L et al (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 70:1389-1394
64. Van der Linden MPM, Le Cessie S, Raza K et al (2010) Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 62:3537-3546
65. Van Tuyl LHD, Boers M, Lems WF et al (2010) Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 69:807-812
66. Van der Woude D, Young A, Jayakumar K et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis. Arthritis Rheum 60:2262-2271
67. Van Dongen H, Aken J van, Lard LR et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424-1432
68. Vermeer M, Kuper IH, Hoekstra M et al (2011) Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the dutch rheumatoid arthritis monitoring remission induction cohort study. Arthritis Rheum 63:2865-2872
69. Verschueren P, Esselens G, Westhovens R (2009) Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis an observational study. Scand J Rheum 38:166-172
70. Visser K, Heijde D van der (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094-1099
71. Visser K, Goekoop-Ruiterman YP, Vries-Bouwstra JK de et al (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 69:1333-1337
72. Ward MM, Leigh JP, Fries JF (1993) Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care. Arch Intern Med 153:2229-2237
73. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371-3380
74. Wollenhaupt J, Alten R, Burckhardt H et al (2007) Aktuelle Therapiestrategien bei rheumatoider Arthritis. Entzündung rasch beherrschen ist entscheidend für die Prognose. MMW Fortschritte Medizin 148:38-42
75. Wollenhaupt J, Alten R, Backhaus M et al (2009) Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen. Akt Rheumatol 34:234-239